Literature DB >> 17902151

Recent changes in the treatment of patients with advanced laryngeal cancer.

Eric M Genden1, Alfio Ferlito, Alessandra Rinaldo, Carl E Silver, Johannes J Fagan, Carlos Suárez, Johannes A Langendijk, Jean Louis Lefebvre, Patrick J Bradley, C René Leemans, Amy Y Chen, Jemy Jose, Gregory T Wolf.   

Abstract

Since the original data from the Department of Veterans Affairs Laryngeal Cancer Study Group demonstrated that nonsurgical therapy could achieve survival rates comparable to total laryngectomy in selected cases, there has been a progressive increase in employment of nonsurgical therapy for the management of advanced laryngeal cancer. Both neoadjuvant chemotherapy followed by conventionally fractionated or hyperfractioned radiotherapy for chemotherapy responders, or simultaneously administered chemoradiation has resulted in a significant number of patients who achieved cure while preserving their larynges. Nevertheless, combined chemotherapy and external beam radiation is associated with a variety of acute and chronic sequelae that can have a debilitating impact on function and quality of life. Although no therapeutic option is without risk, the decision regarding the modality of therapy for a patient with advanced laryngeal cancer should prompt a careful review of the current surgical techniques available for treatment. Data on quality of life and aging, as well as advances in minimally invasive surgical techniques, are available today that were not available at the time of the Veterans study. Selection of optimal therapy is often complex and raises the question whether the pendulum may have swung too far in the direction of nonsurgical therapy for advanced laryngeal cancer. This article reviews the current options available for a patient with advanced laryngeal cancer and discusses the impact of therapy. Copyright (c) 2007 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17902151     DOI: 10.1002/hed.20715

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  17 in total

1.  Combined modality therapy for laryngeal cancer with superselective intra-arterial cisplatin infusion and concomitant radiotherapy.

Authors:  Shigenari Taki; Akihiro Homma; Fumiyuki Suzuki; Nobuhiko Oridate; Hiromitsu Hatakeyama; Takatsugu Mizumachi; Satoshi Kano; Jun Furusawa; Tomohiro Sakashita; Naoya Inamura; Daisuke Yoshida; Rikiya Onimaru; Hiroki Shirato; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2011-10-01       Impact factor: 3.402

2.  [Recent advances in the treatment of laryngeal and hypopharyngeal carcinoma].

Authors:  H E Eckel
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

3.  Which is the most reliable diagnostic modality for detecting locally residual or recurrent laryngeal squamous cell carcinoma after (chemo)radiotherapy?

Authors:  Peter Zbären; Remco de Bree; Robert P Takes; Alessandra Rinaldo; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-21       Impact factor: 2.503

4.  Multi-modality management for loco-regionally advanced laryngeal and hypopharyngeal cancer: balancing the benefit of efficacy and functional preservation.

Authors:  Wei Qian; Guopei Zhu; Yulong Wang; Xiaoshen Wang; Qinghai Ji; Yu Wang; Shengjin Dou
Journal:  Med Oncol       Date:  2014-08-18       Impact factor: 3.064

5.  Quantitative pretreatment CT volumetry: Association with oncologic outcomes in patients with T4a squamous carcinoma of the larynx.

Authors:  Jay C Shiao; Abdallah S R Mohamed; Jay A Messer; Katherine A Hutcheson; Jason M Johnson; Heiko Enderling; Mona Kamal; Benjamin W Warren; Brian Pham; William H Morrison; Mark E Zafereo; Amy C Hessel; Stephen Y Lai; Merril S Kies; Renata Ferrarotto; Adam S Garden; Donald F Schomer; G Brandon Gunn; Jack Phan; Steven J Frank; Beth M Beadle; Randal S Weber; Jan S Lewin; David I Rosenthal; Clifton D Fuller
Journal:  Head Neck       Date:  2017-05-02       Impact factor: 3.147

6.  Treatment complications and survival in advanced laryngeal cancer: a population-based analysis.

Authors:  Caitriona B O'Neill; James P O'Neill; Coral L Atoria; Shrujal S Baxi; Martin C Henman; Ian Ganly; Elena B Elkin
Journal:  Laryngoscope       Date:  2014-10-04       Impact factor: 3.325

7.  Evaluation of the revised TNM classification in advanced laryngeal cancer.

Authors:  G Psychogios; F Waldfahrer; A Bozzato; H Iro
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-01       Impact factor: 2.503

8.  Staging primary head and neck cancers with (18)F-FDG PET/CT: is intravenous contrast administration really necessary?

Authors:  Keisuke Yoshida; Akiko Suzuki; Toshiyuki Nagashima; Jin Lee; Choichi Horiuchi; Mamoru Tsukuda; Tomio Inoue
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-08       Impact factor: 9.236

9.  Social withdrawal after laryngectomy.

Authors:  Helge Danker; Dorit Wollbrück; Susanne Singer; Michael Fuchs; Elmar Brähler; Alexandra Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-09-16       Impact factor: 2.503

Review 10.  Causes of death of patients with laryngeal cancer.

Authors:  Alfio Ferlito; Missak Haigentz; Patrick J Bradley; Carlos Suárez; Primož Strojan; Gregory T Wolf; Kerry D Olsen; William M Mendenhall; Vanni Mondin; Juan P Rodrigo; Carsten C Boedeker; Marc Hamoir; Dana M Hartl; Jennifer L Hunt; Kenneth O Devaney; Lester D R Thompson; Alessandra Rinaldo; Robert P Takes
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-04-17       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.